Interestingly, EZH2, IDH1, IDH2 mutations are also included in the prognostic scores in PMF [12, 13], and NFE2 mutations were previously reported to be associated with a decreased transformation-free survival in a cohort of MPN patients [32]. Here, NFE2 is linked to myeloproliferative neoplasm.